Hemophilia A +/- Inhibitors | Disease Landscape & Forecast | G7 | 2024
The acceptance of Roche / Chugai’s nonfactor bispecific antibody Hemlibra as a key treatment for hemophilia A has changed the treatment landscape. Hemlibra has been transformative for many inhibitor patients who were on bypass agent prophylaxis, providing improved treatment outcomes. It is also a more-convenient prophylaxis option for noninhibitor patients due to its lower dosing frequency and SC administration. The next 10 years will be exciting for the hemophilia A (with and without inhibitors) therapy market owing to the entry of an extended half-life factor VIII product (Sanofi / Sobi’s Altuviiio / Altuvoct), several nonfactor agents (Sanofi’s fitusiran, Pfizer’s marstacimab, and Novo Nordisk’s concizumab and Mim8), and gene therapies (BioMarin’s Roctavian, Pfizer / Sangamo Therapeutics’ giroctocogene fitelparvovec). Supported by insights from thought leaders, we assess the impact of new drugs on the treatment of hemophilia A.
Questions answered
- What is the current treatment landscape for hemophilia A? What are physicians’ experience and satisfaction levels with key therapies?
- How has Hemlibra changed the treatment landscape for hemophilia A for patients with and without inhibitors?
- What clinical roles will Altuviiio, concizumab, fitusiran, marstacimab, Mim8, and gene therapy play in the evolving hemophilia A treatment landscape?
- How will the management of patients with and without inhibitors change when new treatment options become available?
- How will the factor VIII concentrate market evolve?
- How will nonfactor treatment options impact the multitude of brands competing for patient share?
Geography: United States, EU5, Japan
Primary research: 19 country-specific interviews with thought-leading hematologists and supported by survey data collected for this and other Clarivate research
Epidemiology: Diagnosed prevalence of hemophilia A +/-inhibitors by country, population segmentation by disease severity and inhibitor titer
Forecast: 10-year, annualized, drug-level sales and patient share of key hemophilia A therapies through 2033, segmented by brands and epidemiological subpopulations
Drug treatments: Coverage of select current and emerging therapies
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.
Key features
Disease Landscape & Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
